鞍石生物闯关科创板IPO 拟募资24.5亿元

Core Viewpoint - Anshi Biotech has been accepted for IPO on the Sci-Tech Innovation Board, aiming to raise 2.45 billion yuan, and is transitioning into a comprehensive innovative pharmaceutical company while currently operating at a loss [1][4]. Group 1: Company Overview - Anshi Biotech is an innovative biopharmaceutical company focused on oncology and other diseases with significant unmet clinical needs, aiming to provide high-quality innovative anti-tumor drugs through efficient self-research [4]. - The company has a drug pipeline that includes Wanbirui (Bertinib), which has been commercialized, and Andai Aitini, which is in the new drug listing review stage, along with two other drugs (ANS01 and ANS03) in clinical research [4]. Group 2: Financial Performance - As of the report date, Anshi Biotech has not yet achieved profitability, with a cumulative unabsorbed loss of 782 million yuan. The projected net profits (before and after non-recurring losses) for 2022 to Q1 2025 are -164 million yuan, -283 million yuan, -479 million yuan, and -91.65 million yuan respectively [4]. - The company completed a B+ round of equity financing in December 2024, with a post-investment valuation of 5.25 billion yuan [5]. Group 3: Recent Developments - Since the B+ round financing, Anshi Biotech's main product Wanbirui (Bertinib) received conditional approval for treating MET-amplified NSCLC, and Andai Aitini successfully submitted a new drug application with priority review status [5]. - The company has initiated a Phase III clinical trial for the combination of Bertinib and Andai Aitini for treating EGFR-TKI treatment failure with MET amplification/overexpression NSCLC, which has been granted breakthrough therapy designation [5]. Group 4: IPO Purpose - The IPO aims to raise 2.45 billion yuan for new drug research and development projects, as well as to supplement working capital [6].